Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

[Severe oral mucositis in a patient with HIV infection].

Ehlert N, Seilmaier M, Guggemos W, Löscher T, Meurer A, Wendtner CM.

Dtsch Med Wochenschr. 2013 Aug;138(31-32):1601-5. doi: 10.1055/s-0033-1343296. Epub 2013 Jul 24. German.

PMID:
23884748
2.

Leishmania infection can hamper immune recovery in virologically suppressed HIV-infected patients.

Gianotti N, Maillard M, Gaiera G, Bestetti A, Cernuschi M, De Bona A, Lazzarin A, Cinque P, Bossolasco S.

New Microbiol. 2008 Jul;31(3):435-8.

3.

Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.

Sinha PK, van Griensven J, Pandey K, Kumar N, Verma N, Mahajan R, Kumar P, Kumar R, Das P, Mitra G, Flevaud L, Ferreyra C, Remartinez D, Pece M, Palma PP.

Clin Infect Dis. 2011 Oct;53(7):e91-8. doi: 10.1093/cid/cir521.

4.

Successful therapeutic splenectomy in an HIV patient with relapsing visceral leishmaniasis.

Alon D, Chowers M.

Int J STD AIDS. 2012 Apr;23(4):289-90. doi: 10.1258/ijsa.2009.009234.

PMID:
22581957
5.

Liposomal amphotericin B as first line and secondary prophylactic treatment for visceral leishmaniasis in a patient infected with HIV.

Borrelli P, Imperato A, Murdaca G, Scudeletti M.

Ann Ital Med Int. 2000 Apr-Jun;15(2):169-71.

PMID:
10920508
6.

Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.

Rihl M, Stoll M, Ulbricht K, Bange FC, Schmidt RE.

J Infect. 2006 Jul;53(1):e25-7. Epub 2005 Nov 7.

PMID:
16274744
7.

Mucosal Leishmania infantum infection.

Richter J, Hanus I, Häussinger D, Löscher T, Harms G.

Parasitol Res. 2011 Sep;109(3):959-62. doi: 10.1007/s00436-011-2356-x. Epub 2011 Apr 16.

PMID:
21499751
8.

Gingival ulcers as first manifestation of leishmaniasis and HIV infection.

Montineri A, La Rosa R, Larocca L, Brisolese V, Brancati G, Fatuzzo F, Nigro L.

AIDS. 2008 Jan 2;22(1):160-1. No abstract available.

PMID:
18090409
9.

Membranoproliferative glomerulonephritis due to visceral leishmaniasis in an HIV patient.

Enríquez R, Sirvent AE, Padilla S, Toro P, Sánchez M, Millán I.

Am J Case Rep. 2015 Jan 9;16:8-11. doi: 10.12659/AJCR.892641.

10.

Leishmaniasis of the tongue treated with liposomal amphotericin B.

Baily GG, Pitt MA, Curry A, Haboubi NY, Tuffin JR, Mandal BK.

J Infect. 1994 May;28(3):327-31.

PMID:
8089522
11.

[Diffuse cutaneous leishmaniasis in a patient with AIDS].

Pérez C, Solías Y, Rodríguez G.

Biomedica. 2006 Dec;26(4):485-97. Spanish. Erratum in: Biomedica. 2007 Mar;27(1):149.

PMID:
17315475
12.

Ultrasensitive real-time PCR for the clinical management of visceral leishmaniasis in HIV-Infected patients.

Molina I, Fisa R, Riera C, Falcó V, Elizalde A, Salvador F, Crespo M, Curran A, López-Chejade P, Tebar S, Pérez-Hoyos S, Ribera E, Pahissa A.

Am J Trop Med Hyg. 2013 Jul;89(1):105-10. doi: 10.4269/ajtmh.12-0527. Epub 2013 Apr 29.

13.

Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.

Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, Ouellette M.

Clin Infect Dis. 2009 Jan 15;48(2):e16-22. doi: 10.1086/595710.

14.

Visceral Leishmaniasis and HIV coinfection in East Africa.

Diro E, Lynen L, Ritmeijer K, Boelaert M, Hailu A, van Griensven J.

PLoS Negl Trop Dis. 2014 Jun 26;8(6):e2869. doi: 10.1371/journal.pntd.0002869. eCollection 2014 Jun. Review.

15.

Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.

Ritmeijer K, ter Horst R, Chane S, Aderie EM, Piening T, Collin SM, Davidson RN.

Clin Infect Dis. 2011 Dec;53(12):e152-8. doi: 10.1093/cid/cir674. Epub 2011 Oct 19.

16.

Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain?

Medrano FJ, Hernández-Quero J, Jiménez E, Pineda JA, Rivero A, Sánchez-Quijano A, Velez ID, Viciana P, Castillo R, Reyes MJ, et al.

AIDS. 1992 Dec;6(12):1499-503.

PMID:
1362880
17.

[Visceral leishmaniasis in patient with HIV infection].

Olea P, Pinilla J.

Rev Chilena Infectol. 2013 Apr;30(2):216-20. doi: 10.4067/S0716-10182013000200013. Spanish. Erratum in: Rev Chilena Infectol. 2013 Aug;30(4):452. Pinilla, Jorge [added].

18.

Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection.

Sindermann H, Engel KR, Fischer C, Bommer W; Miltefosine Compassionate Use Program.

Clin Infect Dis. 2004 Nov 15;39(10):1520-3. Epub 2004 Oct 18.

19.

Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.

Laguna F, López-Vélez R, Pulido F, Salas A, Torre-Cisneros J, Torres E, Medrano FJ, Sanz J, Picó G, Gómez-Rodrigo J, Pasquau J, Alvar J.

AIDS. 1999 Jun 18;13(9):1063-9.

PMID:
10397536
20.

Old world Leishmania infantum cutaneous leishmaniasis unresponsive to liposomal amphotericin B treated with topical imiquimod.

Hervás JA, Martín-Santiago A, Hervás D, Rojo E, Mena A, Rocamora V, Dueñas J.

Pediatr Infect Dis J. 2012 Jan;31(1):97-100. doi: 10.1097/INF.0b013e31822dfbf7.

PMID:
21829140
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk